Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.36 and traded as low as $1.39. Trevena shares last traded at $1.39, with a volume of 1,840 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on TRVN shares. HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th. StockNews.com initiated coverage on shares of Trevena in a report on Tuesday. They issued a “sell” rating for the company.
View Our Latest Report on TRVN
Trevena Stock Up 6.7 %
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- Investing In Automotive Stocks
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- How to Calculate Inflation Rate
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.